

## COMMUNICATION

[View Article Online](#)  
[View Journal](#) | [View Issue](#)



Cite this: *Nanoscale Adv.*, 2022, **4**, 5021

Received 17th August 2022  
Accepted 3rd October 2022

DOI: 10.1039/d2na00549b  
[rsc.li/nanoscale-advances](http://rsc.li/nanoscale-advances)

Hypoxia, a characteristic hallmark of solid tumours, restricts the therapeutic effect of photodynamic therapy (PDT) for cancer treatment. To address this issue, a facile and nanosized oxygen ( $O_2$ ) bubble template is established by mixing oxygenated water and water-soluble solvents for guiding hollow polydopamine (HPDA) synthesis, and  $O_2$  is encapsulated in the cavity of HPDA. HPDA with abundant catechol is designed as a carrier for zinc phthalocyanine (ZnPc, a boronic acid modified photosensitizer) via borate ester bonds to fabricate nanomedicine (denoted as HZNPs). The *in vitro* and *in vivo* results indicate that  $O_2$ -evolving HZNPs could alleviate tumour hypoxia and enhance PDT-anticancer efficiency. Melanin-like HPDA with a photothermal conversion rate ( $\eta$ ) of 38.2% shows excellent synergistic photothermal therapy (PTT) efficiency in cancer treatment.

## Introduction

Malignant cellular proliferation and vascular malformation lead to hypoxia formation in solid tumours.<sup>1,2</sup> Insufficient oxygen ( $O_2$ ) supply and consumption induce the invasion and metastasis of tumour cells.<sup>3,4</sup> Hypoxia severely limits the

treatment outcome of  $O_2$ -mediated cancer therapies, especially photodynamic therapy (PDT).<sup>5</sup>

Great efforts have been made to alleviate tumour hypoxia for enhancing drug therapy efficiency, and these types can be divided into two categories, supplying exogenous  $O_2$  to tumours (carrier or carrier-free) and catalysing endogenous hydrogen peroxide ( $H_2O_2$ ) or  $H_2O$  to generate  $O_2$ .<sup>6-8</sup> Delivering exogenous  $O_2$  to alleviate tumour hypoxia is the most direct and effective method, and hyperbaric  $O_2$  therapy increasing the  $pO_2$  in the plasma and tumour tissues has been used in clinical PDT for cancer treatment.<sup>9</sup> In recent years, haemoglobin (Hb), liposomes and macrovesicle materials were designed as carriers for  $O_2$  delivery. Hb, an iron-rich metalloprotein in red blood cells composed of globin and heme, could highly bind and deliver  $O_2$  in intravenous transmission.<sup>10</sup> However, free Hb is susceptible to auto-oxidation during circulation and results in renal toxicity and cardiovascular complications.<sup>11</sup> Liposomes embedded with microbubbles have been approved by the FDA as an ultrasound contrast agent for echocardiography.<sup>12</sup> Its disadvantage is that the  $O_2$  loading efficiency is approximately 10% by volume, indicating that it is sufficient for delivering potent bioactive gases, such as NO and Xe, but not suitable for  $O_2$ .<sup>13</sup> Compared with liposomes, hollow materials have a core and a high loading efficiency for  $O_2$ . How to fabricate a satisfactory  $O_2$  carrier to alleviate tumour hypoxia is still a big challenge.

Polydopamine (PDA) is an ideal carrier for drug delivery because of its good biocompatibility.<sup>14</sup> PDA formation shares many common characteristics with the melanin synthetic pathway, and its photothermal conversion rate ( $\eta$ ) could reach up to 40%.<sup>15</sup> Under alkaline conditions, dopamine (DA) monomers were oxidized to DA quinone and a five-membered ring, then rearranged to 5,6-dihydroxyindoles and aggregated with other polymers.<sup>16</sup> More importantly, the polymerization rate of DA at the gas-liquid interface is higher than that in the solutions,<sup>17,18</sup> indicating that the  $O_2$  bubble template may guide PDA polymerization. Chen's group reported a method for  $O_2$ -rich PDA microcapsule preparation in 2021, but the micron-sized aggregates limited its further application in cancer treatment.<sup>19</sup>

<sup>a</sup>School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, China. E-mail: [zhanqichen@njucm.edu.cn](mailto:zhanqichen@njucm.edu.cn); [cao\\_peng@njucm.edu.cn](mailto:cao_peng@njucm.edu.cn)

<sup>b</sup>School of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, China

<sup>c</sup>Department of Public Experimental Teaching, Nanjing University of Aeronautics and Astronautics, Nanjing, Jiangsu, 211106, China

<sup>d</sup>Institute of Chemical Industry of Forest Products, Chinese Academy of Forestry, Nanjing, Jiangsu, 210042, China

<sup>e</sup>Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210028, China


<sup>f</sup>Zhenjiang Hospital of Chinese Traditional and Western Medicine, Zhenjiang, Jiangsu, 212002, China

<sup>g</sup>Gaoyou Hospital of Traditional Chinese Medicine, Yangzhou, Jiangsu, 225600, China

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d2na00549b>

‡ Q. C. Zhan and X. Han contributed equally to this work.






**Scheme 1** (A) Schematic diagram of  $O_2$  bubble formation by mixing oxygenated water and water-soluble organic solvents. (B) HZNP fabrication and (C) the mechanism of HZNPs alleviating tumour hypoxia to enhance PDT efficiency.

As shown in Scheme 1, a facile and nanosized  $O_2$  bubble template is reported by mixing oxygenated water and oxygenated water-soluble organic solvents. The  $O_2$  bubble template guided DA polymerization to form hollow PDA (HPDA) and encapsulate  $O_2$  simultaneously. Furthermore, HPDA is designed as a carrier for zinc phthalocyanine (ZnPc) to fabricate pH-responsive nanomedicine (denoted HZNPs). The ZnPc release rate of HZNPs reached 64.9% in a simulated tumour microenvironment. The *in vitro* and *in vivo* results indicated that HZNPs could deliver  $O_2$  to alleviate tumour hypoxia, inhibit the expression of hypoxia-induced factor-1 (HIF-1 $\alpha$ ), and enhance the anticancer efficiency of PDT. Upon the combination of light irradiation (808 nm + 665 nm), HZNP treated groups achieved satisfactory outcomes by PTT and PDT.

## Results and discussion

Gas solubility in solvents is closely related to polarity, and mixing different solvents could change gas solubility, such as water and water-soluble organic solvents.<sup>20–22</sup> Polarity difference changes resulted in gas accumulation which escapes in the form of bubbles.<sup>23</sup> To obtain nanosized  $O_2$  bubbles, the air (mainly  $N_2$  and  $O_2$ ) dissolved in water and water-soluble organic solvents was removed using a vacuum pump. These solvents were replenished with  $O_2$  to form  $O_2$ -rich solutions respectively.

After mixing oxygenated water and four water-soluble alcohols respectively,  $O_2$  solubility in these mixtures was monitored using an  $O_2$  dissolving meter. The results revealed that  $O_2$  solubility decreased and the biggest change was the mixture of *n*-propanol and water (Fig. 1A–D). The excess  $O_2$  escaped from methanol/water, ethanol/water, isopropanol/water, and *n*-propanol/water was  $3.71\text{ mL L}^{-1}$ ,  $5.46\text{ mL L}^{-1}$ ,  $4.97\text{ mL L}^{-1}$  and  $7.14\text{ mL L}^{-1}$ , respectively. We further studied the size and morphology of  $O_2$  bubbles by taking *n*-propanol/water as an instance at different time points. As shown in Fig. 1E, the dynamic light scattering (DLS) distribution showed that the



**Fig. 1** The  $O_2$  solubility and  $O_2$  release behaviours in four types of oxygenated alcohols and water mixtures (A, methanol/water; B, ethanol/water; C, isopropanol/water; D, *n*-propanol/water). (E) The DLS distribution and (F) the corresponding morphology images of  $O_2$  bubbles in the mixture of oxygenated *n*-propanol and water at different time points (2 min; 10 min; 20 min and 60 min; bar = 50  $\mu\text{m}$ ).

sizes of  $O_2$  bubbles were uneven, ranging from 0.7 nm to 5369 nm. These small  $O_2$  bubbles were fragile and fused with other bubbles to form larger bubbles. Interestingly, these  $O_2$  bubbles with an average size of 188.5 nm remained in existence stably for 10 min. Their generation, fusion and escape processes were also confirmed using a microscope (Fig. 1F).

The polymerization rate of DA monomers at the gas–liquid interface is two times faster than that in solution.<sup>17</sup> Therefore, we speculated that  $O_2$  bubbles are promising as a template for guiding DA polymerization to fabricate HPDA. To prove this hypothesis, after mixing oxygenated water and oxygenated *n*-propanol, DA monomers were added to the mixing solution. The PDA formation process was monitored using a transmission electron microscope (TEM). As shown in Fig. 2A, DA cyclization and covalent cross-linking to form composite films at the gas–liquid interface occur. The Raman spectra confirmed that HPDA was similar to eumelanin (Fig. S1†). Compared with PDA nanobowls, HPDA would not break with the increasing pressure inside the  $O_2$  bubbles.<sup>23</sup> However, after removing the  $O_2$  bubble template, DA polymerized to form PDA nanospheres (Fig. S2†). We further utilized the  $O_2$  bubble template generated by mixing other oxygenated water-soluble organic solvents (methanol, alcohol, and isopropanol) with oxygenated water to prepare HPDA successfully (Fig. S3†), indicating the general applicability of the  $O_2$  bubble template for guiding PDA polymerization. The shell thickness of HPDA could be easily controlled by adjusting the reaction time (Fig. S4†).

Furthermore, HPDA was designed as a carrier for ZnPc via boric acid ester to fabricate HZNPs. As shown in Fig. 2B and C, HZNPs were observed by using TEM and a scanning electron microscope (SEM), and HZNPs presented regular hollow structures with an average size of 156.1 nm (Fig. 2E). The elemental mapping patterns of HZNPs showed that C, N and O were derived from HPDA and ZnPc while Zn was derived from ZnPc, confirming the successful preparation of HZNPs (Fig. 2D). In addition, HZNPs showed UV-vis absorption in the B-band (200–300 nm) and Q-band (600–800 nm), which was attributed to the






Fig. 2 (A) The TEM images of HPDA formation at different time points (0 min; 5 min; 10 min; 45 min) in *n*-propanol/water solution. The (B) TEM and (C) SEM images of HZNP (the SEM sample of HZNP was sprayed with platinum powder two times). (D) The elemental mapping analysis of HZNP. (E) The DLS distribution of HZNP in distilled water. (F) The UV-vis absorbance of HPDA, ZnPc and HZNP in distilled water. (G) The zeta potential comparison of HPDA, ZnPc and HZNP in distilled water (all bars are 100 nm).

characteristic  $\pi-\pi^*$  electron transition of ZnPc.<sup>24</sup> The broad-spectrum absorption ability of HPDA resulted in the increasing absorbance of HZNP (Fig. 2F). As shown in Fig. 2G, ZnPc loading in HZNP also increased the zeta potential of HZNP. The inductively coupled plasma spectrometer (ICP) data indicated that the average loading efficiency of ZnPc in HZNP was  $0.2891 \text{ mg mg}^{-1}$  (Table S1†). To further study the stability of HZNP, the DLS distribution of HZNP was detected in PBS and the cell culture medium. As shown in the DLS results, no obvious HZNP aggregation was detected in PBS or DMEM+10% bovine serum, indicating its good stability in these bio-surroundings (Fig. S5†).

HPDA with abundant catechol could form borate ester bonds with ZnPc, and the pH-responsive borate ester bond was broken under acidic conditions.<sup>25</sup> The vigorous metabolism and profound hypoxia in tumour tissue led to cell glycolysis and superfluous acid substance generation.<sup>26,27</sup> Then, pH-triggered ZnPc release behaviours of HZNP were studied under acidic conditions. As shown in Fig. 3A and S6,† the release rate of ZnPc from HZNP increased obviously under acidic conditions while a slight change was observed under normal conditions, and the ZnPc release rate reached 64.9% when the pH is 5.5, which will recover PDT-mediated antitumor activity (Fig. 3A, S6 and S7†).

Even though HPDA has good stability due to its extensive covalent and noncovalent interactions, HPDA could be degraded in  $\text{H}_2\text{O}_2$  aqueous solution because the  $-\text{OH}$  group in HPDA was oxidized to  $\text{C}=\text{O}$  and  $-\text{COOH}$  groups (Fig. S8†). To study the encapsulation ability of HZNP for  $\text{O}_2$ , the Ru(dpp)<sub>3</sub>Cl<sub>2</sub>, a commercial  $\text{O}_2$ -quenching fluorescence probe, was used to detect the  $\text{O}_2$  levels of different samples. As shown in Fig. 3B and S9,† the fluorescence intensity of the HPDA and HZNP




Fig. 3 (A) Time-dependent release behaviours of ZnPc from HZNP in solution with pH ranging from 5.5 to 7.4. (B)  $\text{O}_2$  level in enclosed and hypoxic aqueous solution treated with different drugs (HPDA, ZnPc and HZNP) was measured using Ru(dpp)<sub>3</sub>Cl<sub>2</sub> ( $\text{H}_2\text{O}_2$ , 200  $\mu\text{M}$ ). (C) The  $^1\text{O}_2$  generation ability of different drugs was detected using ADPA under hypoxic conditions (665 nm, LED, 0.45  $\text{W cm}^{-2}$ ). (D) The photothermal images and (E) temperature change of different drugs under light irradiation (808 nm, laser, 1.0  $\text{W cm}^{-2}$ ). (F) The cooling temperature curve of HPDA in distilled water with turn on/off laser irradiation, and the cooling time ( $t$ ) curve versus the negative natural logarithm of the temperature driving force ( $-\ln \theta$ ). (G) Three photothermal conversion cycles of HPDA. (H) The photothermal images of tumour-bearing mice under laser irradiation and (I) the corresponding temperature change curve (808 nm, laser, 0.3  $\text{W cm}^{-2}$ ).

treated groups decreased obviously while the ZnPc treated group showed a slight change, indicating that HPDA and HZNP could increase the  $\text{O}_2$  level under hypoxic conditions. We further investigated the effect of HPDA-mediated PTT on the stability of HZNP. After being dispersed in  $\text{H}_2\text{O}_2$  aqueous solution for 30 min, HZNP decomposed slightly at room temperature (Fig. S10†). In contrast, after laser irradiation for 30 min, HZNP decomposed rapidly, revealing that PTT may promote the  $\text{O}_2$  release and alleviate tumour hypoxia. Singlet oxygen ( $^1\text{O}_2$ ), a pivotal evaluation indicator for the photosensitizer, is positively related to the  $\text{O}_2$  level.<sup>28</sup> After light irradiation, the  $^1\text{O}_2$  generation ability of different drugs was evaluated using 3,3'-(anthracene-9,10-diyl)dipropionic acid (ADPA). As can be seen from Fig. 3C and S11,† the ADPA absorbance bleaching at 378 nm showed that the order of  $^1\text{O}_2$  generation efficiency of different drugs was  $k_{\text{HZNP}} (6.71 \times 10^{-3}) > k_{\text{ZnPc}} (1.67 \times 10^{-3}) > k_{\text{HPDA}} (0.39 \times 10^{-3}) > k_{\text{Control}} (0.34 \times 10^{-3})$ , indicating that the high  $^1\text{O}_2$  generation efficiency of HZNP was attributed to ZnPc and the increasing  $\text{O}_2$  level.

Melanin-like PDA has strong photothermal properties,<sup>29</sup> and the photothermal conversion rate ( $\eta$ ) of HZNP was measured with a photothermal imager. After laser irradiation for 5 min, the temperature of HPDA and HZNP solutions reached up to 67.1 °C and 67.6 °C respectively, while that of ZnPc was 36.2 °C, revealing that the  $\eta$  of HZNP was mainly derived from HPDA (Fig. 3D and E). To calculate the  $\eta$  of HPDA, the absorbance of HPDA was detected to be 0.3073 at 808 nm (Fig. S12†). The temperature of HPDA solution raised to the highest upon laser

irradiation, then, the laser was turned off, and the natural cooling temperature of HPDA solution was recorded at different points of time. The cooling time ( $t$ ) curve *versus* the negative natural logarithm of temperature driving force ( $-\ln \theta$ ) is shown in Fig. 3F. The time constant ( $\tau$ ) for heat transfer in the system was calculated to be 385.73 and the  $\eta$  was determined to be 38.2%. Three photothermal cycles showed that photothermal conversion capacity decreased slightly, indicating that HPDA has good stability (Fig. 3G). Furthermore, the photothermal properties of HZNPs were measured in tumour-bearing mice. After laser irradiation for 9 min, the temperature of the right solid tumour reached up to 45.1 °C, suggesting that HZNPs could kill tumour cells by PTT (Fig. 3H and I).

HZNP alleviating hypoxia behaviour *in vitro* was detected using Ru(dpp)<sub>3</sub>Cl<sub>2</sub> under hypoxic conditions.<sup>30</sup> Compared with others, the fluorescence intensity of the ZnPc treated group increased obviously upon light irradiation because of PDT-depletion of O<sub>2</sub>. However, even though PDT consumed O<sub>2</sub>, the HZNP treated group still showed no fluorescence change, which indicated that O<sub>2</sub> released from HZNPs alleviated intracellular hypoxia (Fig. 4A and B). O<sub>2</sub> is an important component in PDT since the light initiated <sup>1</sup>O<sub>2</sub> generated by photosensitizers needs O<sub>2</sub> motivation.<sup>30</sup> Therefore, we speculated that O<sub>2</sub>-evolving HZNPs could enhance the anticancer activity of PDT. To verify this speculation, Singlet Oxygen Sensor Green (SOSG) was used to measure the intracellular <sup>1</sup>O<sub>2</sub> generation ability of different drugs. Under hypoxic conditions, the HPDA and ZnPc treated groups all showed weak fluorescence while the HZNP treated group showed fluorescence enhancement upon light irradiation (Fig. 4C and D). All these results above indicated that HZNPs released O<sub>2</sub> and improved the generation ability of ZnPc in tumour cells.

To further elucidate drugs' anticancer mechanisms, the intracellular localization of ZnPc and HZNPs was measured using a confocal laser scanning microscope. As shown in Fig. 4E, the colocalization overlap of drugs and probes (Mito-Tracker Green or Lysotracker Blue) suggested that the action site of HZNPs was the lysosome. Cell Counting Kit-8 (CCK8) assay was used to detect drugs' dark toxicity and phototoxicity under normoxic and hypoxic conditions. First of all, we tested the IC<sub>50</sub> value of each formulation. The IC<sub>50</sub> values of light treated groups were remarkably lower than those of non-light treated groups, indicating that light was one crucial factor in damaging tumour cells (Table S2†). Furthermore, all drugs showed no cytotoxicity without light irradiation (Fig. 4F). After different light irradiations, the HPDA treated group and ZnPc treated group showed PTT-induced (808 nm) and PDT-induced (665 nm) 4T1 cell growth inhibition effects, respectively. The HZNPs have combined and more efficient PTT and PDT anti-cancer effects under normoxic conditions (Fig. 4G). In contrast, the PDT-induced cell death rate by ZnPc decreased obviously under hypoxic conditions, and the anticancer efficiency of HZNPs was superior to that of ZnPc, indicating that HZNPs could alleviate tumour hypoxia (Fig. 4H).

The phototoxicity of different drugs *in vivo* was studied in tumour-bearing mice by monitoring the tumour volume change during 14 days of treatment. The metabolism distribution of




Fig. 4 (A) Intracellular O<sub>2</sub> of the drug (HPDA, ZnPc and HZNPs) treated group was detected using Ru(dpp)<sub>3</sub>Cl<sub>2</sub> and (B) the comparative fluorescence intensity under hypoxic conditions (\*\*\*\*P < 0.0001). (C) Intracellular <sup>1</sup>O<sub>2</sub> of different drugs was detected using the SOSG probe and (D) the comparative fluorescence intensity under hypoxic conditions (\*\*P < 0.01; \*P < 0.05). (E) The laser scanning confocal images of drugs (ZnPc or HZNPs) and the subcellular organelles probe (Mito-Tracker Green or Lyso-Tracker Blue) in tumour cells. (F) The cell cytotoxicity evaluation of various drugs using CCK8 assay. The cell phototoxicity of various drugs treated with different light sources under (G) normoxic conditions (\*\*\*\*P < 0.0001 HZNPs treated with 808 nm and HZNPs treated with 665 nm versus HZNPs treated with 808 nm + 665 nm; #####P < 0.0001 ZnPc treated with 665 nm versus HZNPs treated with 665 nm) and (H) hypoxic conditions (\*\*\*\*P < 0.0001 HZNPs treated with 808 nm and HZNPs treated with 665 nm versus HZNPs treated with 808 + 665 nm; #####P < 0.0001 ZnPc treated with 665 nm versus HZNPs treated with 665 nm). (All bars are 10  $\mu$ m; 808 nm, laser, 0.3 W cm<sup>-2</sup>; 665 nm, LED, and 0.45 W cm<sup>-2</sup>).

ZnPc and HZNPs in mice was monitored using an IVIS Lumina LT system. Compared with the ZnPc treated group, the stronger fluorescence intensity of the HZNP treated group suggested that HZNPs have a better retention effect in solid tumours (Fig. 5A, B and S13†). In addition, the relative amount of the Zn element in the main organs and tumours of tumour-bearing mice was measured by inductively coupled plasma mass spectrometry (ICP-MS). The relative amount of the Zn element in tumours treated with HZNPs was 8.16 mg g<sup>-1</sup>, 2.6 times that of the ZnPc treated group (3.15 mg g<sup>-1</sup>). Compared with the ZnPc treated group, HZNPs accumulated in the kidney decreased, which was beneficial to reduce the side effects of ZnPc (Table S3†). Many literature studies reported that nanomedicine accumulated in tumour and inflamed tissue by the enhanced EPR effect.<sup>31,32</sup> Recent scientific studies indicated the passive accumulation of nanomedicines at the tumour site is not as important as the






Fig. 5 (A) The metabolism distribution of ZnPc and HZNPs in main organs and tumours and (B) the comparative fluorescence intensity. (C) The body weight change of mice treated with different drugs during 14 days of treatment. (D) The relative tumour volume ( $V/V_0$ ) change of tumour-bearing mice during 14 days of treatment and (E) the comparison of significant differences using a one-way ANOVA (I, Control; II, HPDA + 808 nm; III, ZnPc + 665 nm; IV, HZNPs + 808 nm; V, HZNPs + 665 nm; VI, HZNPs + 808 nm + 665 nm; 808 nm, laser,  $0.3 \text{ W cm}^{-2}$ ; 665 nm, laser,  $0.32 \text{ W cm}^{-2}$ ). (F) The tumour weight and (G) image of tumour-bearing mice treated with different drugs after 14 days of treatment. (H) H&E staining and (I) TUNEL staining of tumour slides sacrificed from tumour-bearing mice after 14 days of treatment. (J) The immunofluorescence staining of tumour slides treated with HIF-1 $\alpha$  antibodies (Blue, DAPI; Red, HIF-1 $\alpha$  antibody; All bars are 20  $\mu\text{m}$ ).

proposed classical EPR effect because of few gaps along tumour blood vessels.<sup>33</sup> Therefore, the trans endothelial pathway and EPR effect may both contribute to the high accumulation of HZNPs at tumour sites.

There was no body weight decrease in mice in our study (Fig. 5C). The haematoxylin and eosin (H&E) stained tissue slices of main organs dissected from sacrificial mice showed no pathological features (Fig. S14†). The tumour growth inhibition of different drugs was studied by tumour volume tracking and H&E staining. HPDA treated with 808 nm light and ZnPc treated with 665 nm light showed tumour growth suppression to some extent *via* PTT (19.18%) and PDT (27.88%), respectively. The anticancer efficiency (46.29%) of HZNPs + 665 nm was superior to that (27.88%) of ZnPc + 665 nm, which could be ascribed to the hypoxia alleviating ability of HZNPs at tumour sites. The synergistic PTT and PDT of HZNPs achieved the best anticancer efficiency (73.91%, Fig. 5D–G). H&E staining of pathological tumour slices showed the most serious nuclei damage (purple blue, stained with haematoxylin) occurred in the group of HZNPs treated with 808 nm plus 665 nm light irradiation (Fig. 5H). After treatment with different formulations, the cell apoptosis in the excised tumour tissues was studied by means of

TUNEL. As shown in Fig. 5I, the cell apoptosis of the HZNPs + 665 nm treated group was higher than that of the ZnPc + 665 nm treated group, and HZNPs treated with combination light (808 nm + 665 nm) had the best anticancer efficiency, which was consistent with the results of H&E staining. Furthermore, the hypoxia-inducible factor (HIF)-1 $\alpha$  staining assay was used to evaluate the hypoxic condition in the tumours of different groups. The tumour immunofluorescence of ZnPc treated with 665 nm light was stronger than that of control, implying that the  $\text{O}_2$ -depletion of PDT resulted in HIF-1 $\alpha$  overexpression. Even if the PDT process consumed  $\text{O}_2$  in tumours, the immunofluorescence intensity was still weak in the HZNP treated group, indicating that the HIF-1 $\alpha$  expression was inhibited by the  $\text{O}_2$ -evolving HZNPs (Fig. 5J).

## Conclusions

In conclusion, a facile and nanosized  $\text{O}_2$  bubble template was reported by mixing oxygenated water and water-soluble organic solvents.  $\text{O}_2$ -evolving HPDA was prepared based on the nanosized  $\text{O}_2$  bubble template, which would inspire the gas bubble template for guiding materials synthesis. The *in vitro* and *in vivo* results revealed that HZNPs could release  $\text{O}_2$  and alleviate hypoxia to enhance the PDT efficiency. Under a combination of light (808 nm + 665 nm) irradiation, HZNPs achieved synergistic and satisfactory anticancer efficiency, and the tumour growth rate was suppressed up to 73.91% when compared to that of control mice. Our study provides a novel strategy for  $\text{O}_2$  delivery by nanomaterials in cancer treatment.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This research was financially supported by the National Natural Science Foundation of China (grant no. 82104686; 82125037) and Nanjing University of Chinese Medicine (XPT82104686).

## Notes and references

- 1 C. Zhang, W. J. Qin, X. F. Bai and X. Zhang, *Nano Today*, 2020, **35**, 100960.
- 2 X. Li, K. Kwon, T. Guo, Z. Liu and J. Yoon, *Angew. Chem., Int. Ed.*, 2018, **57**, 11522.
- 3 W. Meng, Y. Hao, C. He and G. Zhu, *Mol. Cancer*, 2019, **18**, 1–14.
- 4 E. L. LaGory and A. J. Giaccia, *Nat. Cell Biol.*, 2016, **18**, 356.
- 5 X. Liang, M. Chen, P. Bhattarai, S. Hameed and Z. Dai, *ACS Nano*, 2020, **14**, 13569.
- 6 Y. Wan, L. H. Fu, C. Li, J. Lin and P. J. Huang, *Adv. Mater.*, 2021, **33**, 2103978.
- 7 Y. Cheng, H. Cheng, C. Jiang, X. Qiu, K. Wang, W. Huan, A. Yuan, J. Wu and Y. Q. Hu, *Nat. Commun.*, 2015, **6**, 8785.
- 8 R. Li, C. Zhang, B. Xie, W. Yu, W. Qiu, H. Cheng and X. Zhang, *Biomaterials*, 2019, **194**, 84.



9 I. Moen and L. E. Stuhr, *Target. Oncol.*, 2012, **7**, 233.

10 H. Wang, J. Li, Y. Wang, X. Gong, X. Xu, J. Wang, Y. Li, X. Sha and Z. Zhang, *J. Control. Release*, 2020, **319**, 25.

11 T. Li, X. Jing and Y. Huang, *Macromol. Biosci.*, 2011, **11**, 865.

12 S. M. Fix, M. A. Borden and P. A. Dayton, *J. Control. Release*, 2015, **209**, 139.

13 S. Huang, D. D. McPherson and R. C. MacDonald, *Ultrasound Med. Biol.*, 2008, **34**, 1272.

14 Y. Liu, K. Ai and L. Lu, *Chem. Rev.*, 2014, **114**, 5057.

15 Q. Zhan, X. Shi, J. Zhou, L. Zhou and S. Wei, *Small*, 2019, **15**, 1803926.

16 N. F. Della Vecchia, R. Avolio, M. Alfè, M. E. Errico, A. Napolitano and M. d'Ischia, *Adv. Funct. Mater.*, 2013, **23**, 1331.

17 F. Ponzio, P. Payamyar, A. Schneider, M. Winterhalter, J. Bour, F. Addiego, M. P. Krafft, J. Hemmerle and V. Ball, *J. Phys. Chem. Lett.*, 2014, **5**, 3436.

18 H. Yang, Q. Wu, L. Wan and Z. Xu, *Chem. Commun.*, 2013, **49**, 10522.

19 B. Wu, Z. Sun, J. Wu, J. Ruan, P. Zhao, K. Liu, C. Zhao, J. Sheng, T. Liang and D. Chen, *Angew. Chem., Int. Ed.*, 2021, **60**, 9284.

20 S. Yang, S. M. Dammer, N. Bremond, H. J. Zandvliet, E. S. Kooij and D. J. Lohse, *Langmuir*, 2007, **23**, 7072.

21 S. Karpitschka, E. Dietrich, J. R. Seddon, H. J. Zandvliet, D. Lohse and H. J. Riegler, *Phys. Rev. Lett.*, 2012, **109**, 066102.

22 L. A. Palmer, D. Cookson and R. N. Lamb, *Langmuir*, 2011, **27**, 144.

23 Q. Zhan, X. Shi, D. Fan, L. Zhou and S. Wei, *Chem. Eng. J.*, 2021, **404**, 126443.

24 A. Ogunsipe, D. Maree and T. J. Nyokong, *J. Mol. Struct.*, 2003, **650**, 131.

25 R. Liu, Y. Guo, G. Odusote, F. Qu and R. D. Priestley, *ACS Appl. Mater. Interfaces*, 2013, **5**, 9167.

26 V. Estrella, T. Chen, M. Lloyd, J. Wojtkowiak, H. H. Cornell, A. Ibrahim-Hashim, K. Bailey, Y. Balagurunathan, J. M. Rothberg, B. F. Sloane, J. Johnson, R. A. Gatenby and R. J. Gillies, *Cancer Res.*, 2013, **73**, 1524.

27 R. A. Cardone, V. Casavola and S. J. Reshkin, *Nat. Rev. Cancer*, 2005, **5**, 786.

28 H. Zhao, J. Xu, Y. Wang, C. Sun, L. Bao, Y. Zhao, X. Yang and Y. Zhao, *ACS Nano*, 2022, **16**, 3070.

29 X. Zeng, M. Luo, G. Liu, X. Wang, W. Tao, Y. Lin, X. Ji, L. Nie and L. Mei, *Adv. Sci.*, 2018, **5**, 1800510.

30 H. Chen, J. Tian, W. He and Z. Guo, *J. Am. Chem. Soc.*, 2015, **137**, 1539.

31 H. Maeda, H. Nakamura and J. Fang, *Adv. Drug Delivery Rev.*, 2013, **65**, 71.

32 H. Kang, S. Rho, W. R. Stiles, S. Hu, Y. Baek, D. W. Hwang, S. Kashiwagi, M. S. Kim and H. S. Choi, *Adv. Healthcare Mater.*, 2020, **9**, 1901223.

33 S. Sindhwani, A. M. Syed, J. Ngai, B. R. Kingston, L. Maiorino, J. Rothschild, P. MacMillan, Y. Zhang, N. U. Rajesh, T. Hoang, J. Wu, S. Wilhelm, A. Zilman, S. Gadde, A. Sulaiman, B. Ouyang, Z. Lin, L. Wang, M. Egeblad and W. Chan, *Nat. Mater.*, 2020, **19**, 566.

